August 22, 2017 10:37 AM EDTUpdated 11:01 AM
News Briefing

In­di­v­ior opens up a $30M R&D cen­ter; Lil­ly strikes dis­cov­ery deal with Topas

Shehla Shakoor

Managing Director

⇨ Eli Lil­ly $LLY has turned to Ger­many’s Topas Ther­a­peu­tics for a new dis­cov­ery deal cov­er­ing drugs for in­flam­ma­to­ry or au­toim­mune con­di­tions. As part …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times